Aerie Pharmaceuticals

Durham-based Aerie Pharma is sold to global eye care giant in deal worth $770M

Posted by WRAL TechWire | Aug 23, 2022

Aerie Pharmaceuticals is being sold to eye care giant Alcon in a deal worth some $770 million, the companies announced late Monday night

Earnings reports: Syneos, Aerie, Fathom, Curtiss-Wright, Albemarle, Ingersoll, Brighthouse & more

Posted by WRAL TechWire | Aug 5, 2022

RESEARCH TRIANGLE PARK – Public companies across Noprth Carolina announced earnings this week, including Syneos, Aerie, Fathom, Curtiss-Wright, Albemarle, Ingersoll, Brighthouse and more. Here’s a roundup. Syneos Health MORRISVILLE – Syneos Health Inc. (SYNH) on Tuesday reported second-quarter net income of $77.7 million. On a per-share basis, the Morrisville,...

Life science earnings: BioCryst, Aerie both report losses

Posted by WRAL TechWire | May 6, 2022

BioCryst and Aerie Pharmaceuticals both reported losses this week. Here are the details.

In the news: Lulu, SAS, ChannelAdvisor, Fujifilm Diosynth, Ribometrix, Aerie

Posted by WRAL TechWire | Mar 21, 2022

From new executives to philanthropy and more, Triangle companies are making headlines. Here’s a roundup.

Earnings reports: Chimerix, Bandwidth, Lending Tree, Aerie

Posted by WRAL TechWire | Mar 1, 2022

Triangle and North Carolina firms continue to report quarterly earnings. Here are several of the latest.

Durham eye disease firm’s new CEO comes on board with $5M ‘inducement grant’

Posted by WRAL TechWire | Dec 23, 2021

Aerie Pharmaceuticals is paying a hefty price to secure the services of its new chief executive officer. Here are the details.

Durham eye health firm Aerie Pharma hires veteran exec as CEO

Posted by WRAL TechWire | Dec 16, 2021

Aerie Pharmaceuticals has a new chief executive officer, naming veteran life science executive Raj Kannan to the post almost three months to the day after longtime CEO and chairman Vincente Anido left the company and his board post

Glaucoma treatment deal lands Durham pharma Aerie $88M up front

Posted by WRAL TechWire | Dec 7, 2021

A licensing deal for two eye disease treatments means an $88 million upfront payment for Aerie Pharmaceuticals. Another $75 million will follow if milestones are met, Aerie announced Tuesday.